ES2576692T3 - Derivados bicíclicos de cicloalquildiamina de heteroarilo como inhibidores de las tirosina quinasas de bazo (SYK) - Google Patents

Derivados bicíclicos de cicloalquildiamina de heteroarilo como inhibidores de las tirosina quinasas de bazo (SYK) Download PDF

Info

Publication number
ES2576692T3
ES2576692T3 ES13779364.2T ES13779364T ES2576692T3 ES 2576692 T3 ES2576692 T3 ES 2576692T3 ES 13779364 T ES13779364 T ES 13779364T ES 2576692 T3 ES2576692 T3 ES 2576692T3
Authority
ES
Spain
Prior art keywords
ylamino
pyrido
amino
pyridazin
cyclohexylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13779364.2T
Other languages
English (en)
Spanish (es)
Inventor
Gebhard Thoma
Peter Buehlmayer
Maurice Van Eis
Alexander Baxter Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Tiergesundheit AG
Original Assignee
Novartis Tiergesundheit AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Tiergesundheit AG filed Critical Novartis Tiergesundheit AG
Application granted granted Critical
Publication of ES2576692T3 publication Critical patent/ES2576692T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13779364.2T 2012-08-13 2013-08-12 Derivados bicíclicos de cicloalquildiamina de heteroarilo como inhibidores de las tirosina quinasas de bazo (SYK) Active ES2576692T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682392P 2012-08-13 2012-08-13
US201261682392P 2012-08-13
PCT/IB2013/056589 WO2014027300A1 (en) 2012-08-13 2013-08-12 Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)

Publications (1)

Publication Number Publication Date
ES2576692T3 true ES2576692T3 (es) 2016-07-08

Family

ID=49385306

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13779364.2T Active ES2576692T3 (es) 2012-08-13 2013-08-12 Derivados bicíclicos de cicloalquildiamina de heteroarilo como inhibidores de las tirosina quinasas de bazo (SYK)

Country Status (14)

Country Link
US (2) US9315500B2 (zh)
EP (1) EP2882747B1 (zh)
JP (1) JP6236083B2 (zh)
KR (1) KR20150042256A (zh)
CN (1) CN104520297B (zh)
AU (1) AU2013303824B2 (zh)
BR (1) BR112015003058A2 (zh)
CA (1) CA2880790C (zh)
EA (1) EA201590372A1 (zh)
ES (1) ES2576692T3 (zh)
HK (1) HK1209421A1 (zh)
IN (1) IN2015DN00950A (zh)
MX (1) MX2015002006A (zh)
WO (1) WO2014027300A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6236083B2 (ja) * 2012-08-13 2017-11-22 ノバルティス ティーアゲズントハイト アーゲー 脾臓チロシンキナーゼ(syk)の阻害剤としての二環式ヘテロアリールシクロアルキルジアミン誘導体
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
JP2009530342A (ja) * 2006-03-20 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー Btkおよびsyk蛋白キナーゼを阻害する方法
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2011014795A2 (en) * 2009-07-30 2011-02-03 Irm Llc Compounds and compositions as syk kinase inhibitors
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
MY173494A (en) 2009-10-29 2020-01-29 Genosco Kinase inhibitors
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
JP6236083B2 (ja) * 2012-08-13 2017-11-22 ノバルティス ティーアゲズントハイト アーゲー 脾臓チロシンキナーゼ(syk)の阻害剤としての二環式ヘテロアリールシクロアルキルジアミン誘導体

Also Published As

Publication number Publication date
BR112015003058A2 (pt) 2017-07-04
US20160213670A1 (en) 2016-07-28
EA201590372A1 (ru) 2015-05-29
AU2013303824B2 (en) 2016-03-31
WO2014027300A1 (en) 2014-02-20
AU2013303824A1 (en) 2015-02-26
US20150218157A1 (en) 2015-08-06
EP2882747A1 (en) 2015-06-17
CN104520297A (zh) 2015-04-15
IN2015DN00950A (zh) 2015-06-12
JP6236083B2 (ja) 2017-11-22
US9315500B2 (en) 2016-04-19
CA2880790A1 (en) 2014-02-20
KR20150042256A (ko) 2015-04-20
EP2882747B1 (en) 2016-04-27
CN104520297B (zh) 2016-08-24
CA2880790C (en) 2020-09-08
MX2015002006A (es) 2015-06-02
HK1209421A1 (zh) 2016-04-01
JP2015524838A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
ES2918974T3 (es) Compuestos heteroaromaticos biciclicos como inmunomoduladores
EP3774791B1 (en) Heterocyclic compounds as immunomodulators
ES2751602T3 (es) Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer
ES2737696T3 (es) Pirazolopiridinas y pirazolopirimidinas
ES2731216T3 (es) Nuevos compuestos
JP2022106967A (ja) 癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
ES2576692T3 (es) Derivados bicíclicos de cicloalquildiamina de heteroarilo como inhibidores de las tirosina quinasas de bazo (SYK)
WO2020200158A1 (zh) 用于治疗癌症的氮杂芳环酰胺衍生物
CN110141570A (zh) 药物化合物
EP2861578A1 (en) Compounds and compositions for modulating egfr activity
ES2925473T3 (es) Pirazoles de piridinilo como moduladores de RORyt
CA3147902A1 (en) Heterobicyclic amides as inhibitors of cd38
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
US9290481B2 (en) Monocyclic heteroaryl cycloalkyldiamine derivatives
AU2014295101A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
EP3233862B1 (en) Imidazopyridazine derivatives as pi3kbeta inhibitors
BR112020000010A2 (pt) derivados substituídos de azaindolina como inibidores de nik
JP6586463B2 (ja) PI3Kβ阻害剤としての複素環連結イミダゾピリダジン誘導体
TWI692476B (zh) 環丁基-咪唑啶酮化合物
WO2022171782A1 (en) Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer
BR112019020309A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta